Company intelligence / Profile preview

Bridge BioResearch PLC

London, England, United Kingdomisaric-bridge.replit.app ↗

Ownership: Private
Development stage: Preclinical

Overview

The company conducted a Phase 2a proof of concept study (NCT01342497) to investigate the safety and efficacy of oral BBR-012 in diabetic patients with foot ulcers. The study began in July 2011, but current results are not available[6].

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

isoniazid (BridgeBio Pharma)

Unknown

Partnerships

Unknown

Beyond the preview

Go deeper on Bridge BioResearch PLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bridge BioResearch PLC.

Explore the full profile